Sign up to save your podcasts
Or
Share ResMed (ASX:RMD) Result Analyst Comments: Reporting Season, August 2023
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ResMed (ASX:RMD) Result Analyst Comments: Reporting Season, August 2023
Morgans Senior Analyst Dr Derek Jellinek gives an update on ResMed's mixed 4Q, as strong sales across all product lines failed to translate into operating leverage.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
View all episodes
By Morgans Financial LimitedMorgans Senior Analyst Dr Derek Jellinek gives an update on ResMed's mixed 4Q, as strong sales across all product lines failed to translate into operating leverage.
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU
Check out more from Morgans:
Visit the Morgans website: www.morgans.com.au
Check out our blog: www.morgans.com.au/Blog
On Facebook: www.facebook.com/MorgansAU
On Instagram: www.instagram.com/Morgans.Australia
On Twitter: twitter.com/MorgansAU